Clinical Trial Update: Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and biological activity of ATYR1940 in early-onset facioscapulohumeral muscular dystrophy (FSHD) has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• ATYR1940

Snippet

Sponsor: aTyr Pharma, Inc. | Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-19